BC Cancer Agency Developing Sequencing-Based AML Test to Stratify Patients for Different Treatments | GenomeWeb

By Monica Heger

This story was originally published Sept. 13.

In order to guide treatment for acute myeloid leukemia patients who have received an uncertain prognosis, researchers at the British Columbia Cancer Agency are developing a sequencing-based test to determine which patients should receive chemotherapy and which should receive stem cell transplantation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.